Last reviewed · How we verify

NCT06967779

The Relationship Between Delirium and BDNF in Coronary Artery Bypass Graft Surgery

Completed Last updated 15 May 2025
What this trial tests

trial in Delirium - Postoperative in 107 participants. Completed in 1 July 2024.

Timeline
1 July 2021
Primary endpoint
1 July 2023
1 July 2024

Quick facts

Lead sponsorPomeranian Medical University Szczecin
StatusCompleted
Study typeOBSERVATIONAL
Enrollment107
Start date1 July 2021
Primary completion1 July 2023
Estimated completion1 July 2024
Sites1 location across Poland

Conditions studied

Sponsor

Pomeranian Medical University Szczecin

Who can join

18 and older, any sex, with Delirium - Postoperative or BDNF. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is aimed at finding a correlation between postoperative delirium occurrence, severity and duration after cardiac surgery and the level of brain-derived neurotrophic factor (BDNF) in plasma as a marker of brain injury induced by cardio-pulmonary by-pass and its association with genetic predisposition in patients undergoing coronary artery bypass grafting (CABG) carrying BDNF gene polymorphism (Val66Met).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Delirium - Postoperative

Currently open trials in the same condition.

Other Pomeranian Medical University Szczecin trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06967779.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing